Drugs / Nucleo CMP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07304453 | Jan → Jul 2024 | neuropathy, painful, trigeminal neuralgia | Karbala University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nucleo CMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07304453 ↗ |
| Known as | cytidine monophosphate | “Nucleo CMP (cytidine monophosphate)” NCT07304453 ↗ |
| Modality | Other / unclassified | “a combination of nucleotides (cytidine monophosphate) and neurotropic B-vitamins (B1, B6, B12)” NCT07304453 ↗ |
| Route | Oral | “administered orally with meals” NCT07304453 ↗ |